+1 credit
| Version | Summary | Created by | Modification | Content Size | Created at | Operation |
|---|---|---|---|---|---|---|
| 1 | Jack Zhong | -- | 165 | 2026-10-19 10:59:09 | | | |
| 2 | Jack Zhong | -9 word(s) | 156 | 2026-10-19 11:05:30 | | |
Video Upload Options
Heparin
EditHeparin is a strongly sulfated glycosaminoglycan used clinically as an anticoagulant, and it acts by accelerating the inhibition of thrombin by antithrombin. Its activity depends on a specific pentasaccharide sequence that binds antithrombin, so not every chain in a commercial preparation is active [1]. The molecule is heterogeneous in chain length and in sulfate content, and this heterogeneity is the main reason the potency is expressed in international units rather than by mass [2]. Because it is strongly anionic, heparin binds to many proteins and to positively charged surfaces, which is the basis of its role as a coating on blood-contacting devices [3]. Immobilised on a polymer surface it reduces thrombus formation without being released into the circulation, although the long-term stability of the coating is uncertain [4]. Its short half-life in vivo has driven the development of low-molecular-weight fractions and of synthetic analogues that retain the antithrombin-binding sequence [5].
References
- Wei, H.; Han, L.; Ren, J.; Jia, L. Anticoagulant Surface Coating Using Composite Polysaccharides with Embedded Heparin-Releasing Mesoporous Silica. ACS Applied Materials & Interfaces 2013, 5, 12571-12578. [CrossRef]
- Mulinti, P.; Kalita, D.; Hasan, R.; Quadir, M.; Wang, Y.; Brooks, A. Development and processing of novel heparin binding functionalized modified spider silk coating for catheter providing dual antimicrobial and anticoagulant properties. Materialia 2020, 14, 100937. [CrossRef]
- Reardon, B.; Pasalic, L.; Lippi, G.; Favaloro, E.J. Heparin Anticoagulant Therapy and Its Monitoring. Biomolecules 2026, 16, 425. [CrossRef]
- Li, C.; Zhang, M.; Liu, X.; Zhao, W.; Zhao, C. Immobilization of heparin-mimetic biomacromolecules on Fe3O4 nanoparticles as magnetic anticoagulant via mussel-inspired coating. Materials Science and Engineering: C 2020, 109, 110516. [CrossRef]
- Palm, M.; Mattsson, C.; Svahn, C.M.; Weber, M. Bleeding Times in Rats Treated with Heparin, Heparin Fragments of High and Low Anticoagulant Activity and chemically Modified Heparin Fragments of Low Anticoagulant Activity. Thrombosis and Haemostasis 1990, 64, 127-132. [CrossRef]
